Carcinogenicity testing of atrazine: preliminary report on a 13-month study on male Swiss albino mice treated by intraperitoneal administration.
A statistically significant increase (p less than 0.001) of lymphomas (4 of plasmacell type and two of histiocytic type) was found in a group of 30 Swiss albino mice which were given intraperitoneally 0.25 cc of a 2 ppm solution of atrazine for 13 times every third day to total administration of 0.26 mg of Atrazine/kg of body weight. Lymphomas arising in two groups of 50 controls was 0 and 1 respectively.